Monte Rosa Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Monte Rosa Therapeutics, Inc. (GLUE) reported Increase Decrease In Operating Lease Liability of -$874.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$440.00K.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$434.00K.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$298.00K.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$354.00K.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.08M.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.35M, a 113.01% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was $10.37M.
- Monte Rosa Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$181.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$440.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$874.00K 10-Q · filed 2026-08-06 | -$1.17M derived: sum of 3 quarters · filed 2026-08-06 | -$1.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$434.00K 10-Q · filed 2026-05-07 | -$732.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.09M derived: sum of 3 quarters · filed 2026-05-07 | -$1.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$652.00K derived: sum of 2 quarters · filed 2026-03-17 | -$796.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.08M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$354.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$498.00K derived: sum of 2 quarters · filed 2026-08-06 | -$781.00K 10-Q · filed 2025-11-06 | -$1.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$427.00K 10-Q · filed 2026-08-06 | -$878.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$283.00K 10-Q · filed 2026-05-07 | -$734.00K derived: sum of 2 quarters · filed 2026-05-07 | -$863.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$580.00K derived: sum of 2 quarters · filed 2026-03-17 | -$877.00K derived: sum of 3 quarters · filed 2026-03-17 | -$1.35M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$426.00K derived: sum of 2 quarters · filed 2025-11-06 | -$897.00K 10-Q · filed 2025-11-06 | -$531.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$768.00K 10-Q · filed 2025-08-07 | -$402.00K derived: sum of 3 quarters · filed 2025-08-07 | $396.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$471.00K 10-Q · filed 2025-05-08 | -$105.00K derived: sum of 2 quarters · filed 2025-05-08 | $693.00K derived: sum of 3 quarters · filed 2025-05-08 | $3.00M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.16M derived: sum of 2 quarters · filed 2025-03-20 | $3.47M derived: sum of 3 quarters · filed 2025-03-20 | $10.37M 10-K · filed 2025-03-20 |
| 2023-09-30 | $798.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.10M derived: sum of 2 quarters · filed 2024-11-07 | $10.00M 10-Q · filed 2024-11-07 | $9.84M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.20M 10-Q · filed 2024-08-08 | $9.04M derived: sum of 3 quarters · filed 2024-08-08 | $9.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $6.89M 10-Q · filed 2024-05-09 | $6.73M derived: sum of 2 quarters · filed 2024-05-09 | $6.78M derived: sum of 3 quarters · filed 2024-05-09 | $7.09M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$111.00K derived: sum of 2 quarters · filed 2024-03-14 | $194.00K derived: sum of 3 quarters · filed 2024-03-14 | -$181.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $357.00K derived: sum of 2 quarters · filed 2023-11-09 | -$18.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $305.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$70.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$375.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |